Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients
The novel coronavirus (CoV) severe acute respiratory syndrome (SARS)-CoV-2 outbreak began at the end of 2019 in Wuhan, China, and has spread to over 200 countries. In this multicenter retrospective study, we identified 2190 adult patients admitted for laboratory-confirmed COVID-19 in three participa...
Gespeichert in:
| Veröffentlicht in: | Cell discovery 2020-10, Vol.6 (1), p.77-77, Article 77 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 77 |
|---|---|
| container_issue | 1 |
| container_start_page | 77 |
| container_title | Cell discovery |
| container_volume | 6 |
| creator | Yan, Feifei Huang, Fengming Xu, Jun Yang, Penghui Qin, Yuhao Lv, Jingjun Zhang, Shaogeng Ye, Lu Gong, Ming Liu, Zhibo Wei, Jie Xie, Tuxiu Xu, Kai-Feng Gao, George F. Wang, Fu-Sheng Cai, Lin Jiang, Chengyu |
| description | The novel coronavirus (CoV) severe acute respiratory syndrome (SARS)-CoV-2 outbreak began at the end of 2019 in Wuhan, China, and has spread to over 200 countries. In this multicenter retrospective study, we identified 2190 adult patients admitted for laboratory-confirmed COVID-19 in three participating centers. Multivariate logistic regression was conducted in patients with comorbid hypertension to examine the potential association between clinical outcomes, disease severity, and clinical characteristics with the use of ACEI, ARB, calcium-channel blockers (CCB), beta-blockers (BB), and thiazide diuretics. The clinical outcome, dyspnea, and fatigue were significantly improved in patients, especially elderly patients who were older than 65 years, who took ARB drugs prior to hospitalization compared to patients who took no drugs. The reduction of disease severity of elderly COVID-19 patients was associated with CCB and ACEI users. Clinical indices, including CRP, lymphocyte count, procalcitonin D dimer, and hemoglobin, were significantly improved in elderly ARB users. In addition, the clinical outcomes were statistically significantly improved in patients who took antihypertension drugs ARB, BB, and CCB after statistical adjustment by all ages, gender, baseline of blood pressures, and coexisting medical conditions. Our data indicate that hypertension drugs ARB, ACEI, CCB, and BB might be beneficial for COVID-19 patients. |
| doi_str_mv | 10.1038/s41421-020-00221-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7595708</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2471527156</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-dd909d09c108f09d5cc980dbcc3451caa5f363c3269d3aa5b3f232f95ffb21723</originalsourceid><addsrcrecordid>eNp9kU1vFDEMhkcIRKvSP8ABReLCZSAfk5nkglQtX5Uq9QJco6yT2U01kyxJZtHe-eG4bCmFA4cotvz4ta23aZ4z-ppRod6UjnWctZTTllKOUf-oOeVU9q3UvXr8ID5pzku5oZQyyZVS8mlzIgTXSunhtPlxEWvYHnY-Vx9L2Hvi8rIpxGZPbCkJgq3eke-hbkn2bgFMRlvtRNJSIc0e0ehImHc57bEGU4gBsAxbmy1Un0OpAQoJkfjJ-TwdyOr66-W7lmmyszX4WMuz5slop-LP7_6z5suH959Xn9qr64-Xq4urFrqhq61zmmpHNTCqRowkgFbUrQFEJxlYK0fRCxC8105gthYjF3zUchzXnA1cnDVvj7q7ZT17Bzg728nscphtPphkg_m7EsPWbNLeDFLLgSoUeHUnkNO3xZdq5lDAT5ONPi3F8K7HFTmTDNGX_6A3ackRz0NqQCvw9UjxIwU5lZL9eL8Mo-bWZ3P02aDP5pfP5rbpxcMz7lt-u4qAOAIFS3Hj85_Z_5H9CaiitiY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2471527156</pqid></control><display><type>article</type><title>Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Springer Nature OA Free Journals</source><source>Nature Free</source><source>PubMed Central</source><creator>Yan, Feifei ; Huang, Fengming ; Xu, Jun ; Yang, Penghui ; Qin, Yuhao ; Lv, Jingjun ; Zhang, Shaogeng ; Ye, Lu ; Gong, Ming ; Liu, Zhibo ; Wei, Jie ; Xie, Tuxiu ; Xu, Kai-Feng ; Gao, George F. ; Wang, Fu-Sheng ; Cai, Lin ; Jiang, Chengyu</creator><creatorcontrib>Yan, Feifei ; Huang, Fengming ; Xu, Jun ; Yang, Penghui ; Qin, Yuhao ; Lv, Jingjun ; Zhang, Shaogeng ; Ye, Lu ; Gong, Ming ; Liu, Zhibo ; Wei, Jie ; Xie, Tuxiu ; Xu, Kai-Feng ; Gao, George F. ; Wang, Fu-Sheng ; Cai, Lin ; Jiang, Chengyu</creatorcontrib><description>The novel coronavirus (CoV) severe acute respiratory syndrome (SARS)-CoV-2 outbreak began at the end of 2019 in Wuhan, China, and has spread to over 200 countries. In this multicenter retrospective study, we identified 2190 adult patients admitted for laboratory-confirmed COVID-19 in three participating centers. Multivariate logistic regression was conducted in patients with comorbid hypertension to examine the potential association between clinical outcomes, disease severity, and clinical characteristics with the use of ACEI, ARB, calcium-channel blockers (CCB), beta-blockers (BB), and thiazide diuretics. The clinical outcome, dyspnea, and fatigue were significantly improved in patients, especially elderly patients who were older than 65 years, who took ARB drugs prior to hospitalization compared to patients who took no drugs. The reduction of disease severity of elderly COVID-19 patients was associated with CCB and ACEI users. Clinical indices, including CRP, lymphocyte count, procalcitonin D dimer, and hemoglobin, were significantly improved in elderly ARB users. In addition, the clinical outcomes were statistically significantly improved in patients who took antihypertension drugs ARB, BB, and CCB after statistical adjustment by all ages, gender, baseline of blood pressures, and coexisting medical conditions. Our data indicate that hypertension drugs ARB, ACEI, CCB, and BB might be beneficial for COVID-19 patients.</description><identifier>ISSN: 2056-5968</identifier><identifier>EISSN: 2056-5968</identifier><identifier>DOI: 10.1038/s41421-020-00221-6</identifier><identifier>PMID: 33298897</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>631/250/38 ; 631/337/505 ; Antihypertensives ; Biomedical and Life Sciences ; Calcium ; Cell Biology ; Cell Culture ; Cell Cycle Analysis ; Cell number ; Cell Physiology ; Clinical outcomes ; Coronaviruses ; COVID-19 ; Diuretics ; Drugs ; Dyspnea ; Hemoglobin ; Hypertension ; Life Sciences ; Lymphocytes ; Patients ; Procalcitonin ; Respiration ; Severe acute respiratory syndrome ; Stem Cells</subject><ispartof>Cell discovery, 2020-10, Vol.6 (1), p.77-77, Article 77</ispartof><rights>The Author(s) 2020</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-dd909d09c108f09d5cc980dbcc3451caa5f363c3269d3aa5b3f232f95ffb21723</citedby><cites>FETCH-LOGICAL-c474t-dd909d09c108f09d5cc980dbcc3451caa5f363c3269d3aa5b3f232f95ffb21723</cites><orcidid>0000-0002-3869-615X ; 0000-0002-8043-6685</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595708/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595708/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,861,882,27905,27906,41101,42170,51557,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33298897$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yan, Feifei</creatorcontrib><creatorcontrib>Huang, Fengming</creatorcontrib><creatorcontrib>Xu, Jun</creatorcontrib><creatorcontrib>Yang, Penghui</creatorcontrib><creatorcontrib>Qin, Yuhao</creatorcontrib><creatorcontrib>Lv, Jingjun</creatorcontrib><creatorcontrib>Zhang, Shaogeng</creatorcontrib><creatorcontrib>Ye, Lu</creatorcontrib><creatorcontrib>Gong, Ming</creatorcontrib><creatorcontrib>Liu, Zhibo</creatorcontrib><creatorcontrib>Wei, Jie</creatorcontrib><creatorcontrib>Xie, Tuxiu</creatorcontrib><creatorcontrib>Xu, Kai-Feng</creatorcontrib><creatorcontrib>Gao, George F.</creatorcontrib><creatorcontrib>Wang, Fu-Sheng</creatorcontrib><creatorcontrib>Cai, Lin</creatorcontrib><creatorcontrib>Jiang, Chengyu</creatorcontrib><title>Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients</title><title>Cell discovery</title><addtitle>Cell Discov</addtitle><addtitle>Cell Discov</addtitle><description>The novel coronavirus (CoV) severe acute respiratory syndrome (SARS)-CoV-2 outbreak began at the end of 2019 in Wuhan, China, and has spread to over 200 countries. In this multicenter retrospective study, we identified 2190 adult patients admitted for laboratory-confirmed COVID-19 in three participating centers. Multivariate logistic regression was conducted in patients with comorbid hypertension to examine the potential association between clinical outcomes, disease severity, and clinical characteristics with the use of ACEI, ARB, calcium-channel blockers (CCB), beta-blockers (BB), and thiazide diuretics. The clinical outcome, dyspnea, and fatigue were significantly improved in patients, especially elderly patients who were older than 65 years, who took ARB drugs prior to hospitalization compared to patients who took no drugs. The reduction of disease severity of elderly COVID-19 patients was associated with CCB and ACEI users. Clinical indices, including CRP, lymphocyte count, procalcitonin D dimer, and hemoglobin, were significantly improved in elderly ARB users. In addition, the clinical outcomes were statistically significantly improved in patients who took antihypertension drugs ARB, BB, and CCB after statistical adjustment by all ages, gender, baseline of blood pressures, and coexisting medical conditions. Our data indicate that hypertension drugs ARB, ACEI, CCB, and BB might be beneficial for COVID-19 patients.</description><subject>631/250/38</subject><subject>631/337/505</subject><subject>Antihypertensives</subject><subject>Biomedical and Life Sciences</subject><subject>Calcium</subject><subject>Cell Biology</subject><subject>Cell Culture</subject><subject>Cell Cycle Analysis</subject><subject>Cell number</subject><subject>Cell Physiology</subject><subject>Clinical outcomes</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Diuretics</subject><subject>Drugs</subject><subject>Dyspnea</subject><subject>Hemoglobin</subject><subject>Hypertension</subject><subject>Life Sciences</subject><subject>Lymphocytes</subject><subject>Patients</subject><subject>Procalcitonin</subject><subject>Respiration</subject><subject>Severe acute respiratory syndrome</subject><subject>Stem Cells</subject><issn>2056-5968</issn><issn>2056-5968</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kU1vFDEMhkcIRKvSP8ABReLCZSAfk5nkglQtX5Uq9QJco6yT2U01kyxJZtHe-eG4bCmFA4cotvz4ta23aZ4z-ppRod6UjnWctZTTllKOUf-oOeVU9q3UvXr8ID5pzku5oZQyyZVS8mlzIgTXSunhtPlxEWvYHnY-Vx9L2Hvi8rIpxGZPbCkJgq3eke-hbkn2bgFMRlvtRNJSIc0e0ehImHc57bEGU4gBsAxbmy1Un0OpAQoJkfjJ-TwdyOr66-W7lmmyszX4WMuz5slop-LP7_6z5suH959Xn9qr64-Xq4urFrqhq61zmmpHNTCqRowkgFbUrQFEJxlYK0fRCxC8105gthYjF3zUchzXnA1cnDVvj7q7ZT17Bzg728nscphtPphkg_m7EsPWbNLeDFLLgSoUeHUnkNO3xZdq5lDAT5ONPi3F8K7HFTmTDNGX_6A3ackRz0NqQCvw9UjxIwU5lZL9eL8Mo-bWZ3P02aDP5pfP5rbpxcMz7lt-u4qAOAIFS3Hj85_Z_5H9CaiitiY</recordid><startdate>20201029</startdate><enddate>20201029</enddate><creator>Yan, Feifei</creator><creator>Huang, Fengming</creator><creator>Xu, Jun</creator><creator>Yang, Penghui</creator><creator>Qin, Yuhao</creator><creator>Lv, Jingjun</creator><creator>Zhang, Shaogeng</creator><creator>Ye, Lu</creator><creator>Gong, Ming</creator><creator>Liu, Zhibo</creator><creator>Wei, Jie</creator><creator>Xie, Tuxiu</creator><creator>Xu, Kai-Feng</creator><creator>Gao, George F.</creator><creator>Wang, Fu-Sheng</creator><creator>Cai, Lin</creator><creator>Jiang, Chengyu</creator><general>Springer Singapore</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3869-615X</orcidid><orcidid>https://orcid.org/0000-0002-8043-6685</orcidid></search><sort><creationdate>20201029</creationdate><title>Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients</title><author>Yan, Feifei ; Huang, Fengming ; Xu, Jun ; Yang, Penghui ; Qin, Yuhao ; Lv, Jingjun ; Zhang, Shaogeng ; Ye, Lu ; Gong, Ming ; Liu, Zhibo ; Wei, Jie ; Xie, Tuxiu ; Xu, Kai-Feng ; Gao, George F. ; Wang, Fu-Sheng ; Cai, Lin ; Jiang, Chengyu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-dd909d09c108f09d5cc980dbcc3451caa5f363c3269d3aa5b3f232f95ffb21723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>631/250/38</topic><topic>631/337/505</topic><topic>Antihypertensives</topic><topic>Biomedical and Life Sciences</topic><topic>Calcium</topic><topic>Cell Biology</topic><topic>Cell Culture</topic><topic>Cell Cycle Analysis</topic><topic>Cell number</topic><topic>Cell Physiology</topic><topic>Clinical outcomes</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Diuretics</topic><topic>Drugs</topic><topic>Dyspnea</topic><topic>Hemoglobin</topic><topic>Hypertension</topic><topic>Life Sciences</topic><topic>Lymphocytes</topic><topic>Patients</topic><topic>Procalcitonin</topic><topic>Respiration</topic><topic>Severe acute respiratory syndrome</topic><topic>Stem Cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yan, Feifei</creatorcontrib><creatorcontrib>Huang, Fengming</creatorcontrib><creatorcontrib>Xu, Jun</creatorcontrib><creatorcontrib>Yang, Penghui</creatorcontrib><creatorcontrib>Qin, Yuhao</creatorcontrib><creatorcontrib>Lv, Jingjun</creatorcontrib><creatorcontrib>Zhang, Shaogeng</creatorcontrib><creatorcontrib>Ye, Lu</creatorcontrib><creatorcontrib>Gong, Ming</creatorcontrib><creatorcontrib>Liu, Zhibo</creatorcontrib><creatorcontrib>Wei, Jie</creatorcontrib><creatorcontrib>Xie, Tuxiu</creatorcontrib><creatorcontrib>Xu, Kai-Feng</creatorcontrib><creatorcontrib>Gao, George F.</creatorcontrib><creatorcontrib>Wang, Fu-Sheng</creatorcontrib><creatorcontrib>Cai, Lin</creatorcontrib><creatorcontrib>Jiang, Chengyu</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cell discovery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yan, Feifei</au><au>Huang, Fengming</au><au>Xu, Jun</au><au>Yang, Penghui</au><au>Qin, Yuhao</au><au>Lv, Jingjun</au><au>Zhang, Shaogeng</au><au>Ye, Lu</au><au>Gong, Ming</au><au>Liu, Zhibo</au><au>Wei, Jie</au><au>Xie, Tuxiu</au><au>Xu, Kai-Feng</au><au>Gao, George F.</au><au>Wang, Fu-Sheng</au><au>Cai, Lin</au><au>Jiang, Chengyu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients</atitle><jtitle>Cell discovery</jtitle><stitle>Cell Discov</stitle><addtitle>Cell Discov</addtitle><date>2020-10-29</date><risdate>2020</risdate><volume>6</volume><issue>1</issue><spage>77</spage><epage>77</epage><pages>77-77</pages><artnum>77</artnum><issn>2056-5968</issn><eissn>2056-5968</eissn><abstract>The novel coronavirus (CoV) severe acute respiratory syndrome (SARS)-CoV-2 outbreak began at the end of 2019 in Wuhan, China, and has spread to over 200 countries. In this multicenter retrospective study, we identified 2190 adult patients admitted for laboratory-confirmed COVID-19 in three participating centers. Multivariate logistic regression was conducted in patients with comorbid hypertension to examine the potential association between clinical outcomes, disease severity, and clinical characteristics with the use of ACEI, ARB, calcium-channel blockers (CCB), beta-blockers (BB), and thiazide diuretics. The clinical outcome, dyspnea, and fatigue were significantly improved in patients, especially elderly patients who were older than 65 years, who took ARB drugs prior to hospitalization compared to patients who took no drugs. The reduction of disease severity of elderly COVID-19 patients was associated with CCB and ACEI users. Clinical indices, including CRP, lymphocyte count, procalcitonin D dimer, and hemoglobin, were significantly improved in elderly ARB users. In addition, the clinical outcomes were statistically significantly improved in patients who took antihypertension drugs ARB, BB, and CCB after statistical adjustment by all ages, gender, baseline of blood pressures, and coexisting medical conditions. Our data indicate that hypertension drugs ARB, ACEI, CCB, and BB might be beneficial for COVID-19 patients.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>33298897</pmid><doi>10.1038/s41421-020-00221-6</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-3869-615X</orcidid><orcidid>https://orcid.org/0000-0002-8043-6685</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2056-5968 |
| ispartof | Cell discovery, 2020-10, Vol.6 (1), p.77-77, Article 77 |
| issn | 2056-5968 2056-5968 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7595708 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Springer Nature OA Free Journals; Nature Free; PubMed Central |
| subjects | 631/250/38 631/337/505 Antihypertensives Biomedical and Life Sciences Calcium Cell Biology Cell Culture Cell Cycle Analysis Cell number Cell Physiology Clinical outcomes Coronaviruses COVID-19 Diuretics Drugs Dyspnea Hemoglobin Hypertension Life Sciences Lymphocytes Patients Procalcitonin Respiration Severe acute respiratory syndrome Stem Cells |
| title | Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T23%3A34%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antihypertensive%20drugs%20are%20associated%20with%20reduced%20fatal%20outcomes%20and%20improved%20clinical%20characteristics%20in%20elderly%20COVID-19%20patients&rft.jtitle=Cell%20discovery&rft.au=Yan,%20Feifei&rft.date=2020-10-29&rft.volume=6&rft.issue=1&rft.spage=77&rft.epage=77&rft.pages=77-77&rft.artnum=77&rft.issn=2056-5968&rft.eissn=2056-5968&rft_id=info:doi/10.1038/s41421-020-00221-6&rft_dat=%3Cproquest_pubme%3E2471527156%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2471527156&rft_id=info:pmid/33298897&rfr_iscdi=true |